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Abstract 
We report a patient with necrotising scleritis in whom infliximab was used for short-term 
steroid-sparing while rituximab took effect. This enabled disease control without requiring 
an extended period of high-dose corticosteroid administration or the concurrent use of 
cyclophosphamide. 
 
Introduction 
Granulomatosis with polyangiitis (GPA), previously known as Wegener’s 
granulomatosis, is a multi-system autoimmune disease, often associated with anti-
neutrophil cytoplasm antibodies (ANCA), which commonly involves the eye as well as 
the respiratory tract and kidneys. Ophthalmic complications occur in 50–60% of 
patients and typically take the form of necrotising scleritis or granulomatous orbital 
involvement [1]. Ophthalmologists need to be aware that these conditions are 
potentially sight-threatening – some 90% of patients with necrotising scleritis develop 
ocular complications and 50% develop significant visual loss [2]. Suboptimal treatment 
of either condition can lead to serious visual consequences. 
Cyclophosphamide and corticosteroids have been the cornerstones of treatment for 
severe GPA but are associated with treatment-related morbidity and mortality [3]. 
More recent treatment options include the biological agent rituximab, which is a 
monoclonal antibody directed against CD20, a cell surface antigen expressed by many 
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subtypes of B cells, although not by plasma cells. We have recently shown that 
rituximab can be effective in refractory ophthalmic GPA and induce long-lasting disease 
remission, but it takes up to 6 months to work, meaning that additional agents may be 
required to provide disease control in the interim [4]. 
Infliximab belongs to a different class of biological agents, being a monoclonal 
antibody directed against tumour necrosis factor-alpha (TNF-α). It is licensed for the 
treatment of both rheumatoid arthritis and Crohn’s disease in the United States and 
Europe [5] and has also demonstrated efficacy in the treatment of the ANCA-associated 
vasculitides (AAV), such as GPA, although a recent study in which infliximab was added 
to standard therapy in patients with active AAV failed to demonstrate any benefit 
compared to standard therapy alone [6]. Infliximab has been used successfully in the 
treatment of refractory scleritis [7, 8]. 
We report here a patient with necrotising scleritis associated with GPA in whom 
infliximab was used for short-term steroid-sparing while rituximab took effect. This 
enabled disease control without requiring an extended period of high-dose 
corticosteroid administration or the concurrent use of cyclophosphamide, neither of 
which was desirable as a result of his comorbidities and previous treatment history. 
Case Report 
A 71-year-old man was referred to the Hammersmith Hospital Multidisciplinary Vasculitis Clinic 
with necrotising scleritis in the left eye (fig. 1). He had previously been diagnosed with GPA on the 
basis of characteristic renal disease associated with a raised ANCA titre and the presence of anti-PR3 
antibodies. He had previously been treated with cyclophosphamide, and his cumulative dose of 
cyclophosphamide was approximately 20 g. He was initially treated with corticosteroids at a dose of 
1 mg/kg and a cycle of rituximab (MabThera, Hoffmann-La Roche, Ltd.) given as 2 intravenous doses 
of 1 g two weeks apart. After 3 weeks, his necrotising scleritis was still active, despite his B cell count 
having fallen to 0 cells/mm3. We were reluctant to continue his high-dose corticosteroids as he had 
osteoporosis confirmed on DEXA scanning, and treatment with cyclophosphamide was not felt 
desirable in view of his cumulative dose. Therefore, infusions of infliximab (Remicade, Merck & Co.) 
were arranged and given as doses of 5 mg/kg at baseline, 2, 6 and 12 weeks. His necrotising scleritis 
was controlled by week 6 (fig. 2), and his systemic corticosteroids were reduced to 5 mg 
prednisolone/day by week 12. He had his final infusion of infliximab at this point and thereafter was 
maintained on 5 mg prednisolone/day alone for the following 12 months. 
Discussion 
We report a case of necrotising scleritis secondary to GPA, successfully treated with 
infliximab whilst waiting for rituximab to induce disease remission. Importantly, this 
enabled cyclophosphamide to be avoided in the acute phase, as rituximab can take up 
to 6 months to work [4, 5]. This was especially important as the patient had had 
significant previous exposure to cyclophosphamide, increasing his risk of malignancy 
with further treatment. Infliximab rather than etanercept was used as the latter has 
previously been proven not to be effective for the maintenance of remission in patients 
with GPA [5, 9]. In addition, retrospective studies of patients with uveitis treated with 
TNF-α blockade have indicated infliximab to be the more effective treatment in 
ophthalmic disease [10]. 
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There was some concern that the use of two biological agents simultaneously could 
lead to life-threatening infection or malignancy, but there is little in the literature that 
addresses this directly. One recent registry-based study of patients being treated with 
biological agents for rheumatoid arthritis showed their rate of hospitalised infection to 
be 4.6 per 100 person-years, increasing to 7.0 per 100 person-years for the group that 
had ‘switched’ from a different biological agent [11], the situation most analogous to 
the one here. Interestingly, the rate for rituximab was higher at 10.4 episodes per 100 
person-years in this study, falling to 7.1 in switchers; the authors suggested that this 
might represent higher-risk patients being channelled towards rituximab therapy. 
Encouragingly for the treating clinician, analysis showed that patient characteristics 
were a more powerful determinant of the rate of serious infections than specific 
biological drugs or patterns of switching drugs. Similarly, a meta-analysis of patients 
treated with TNF-α blockade in rheumatoid arthritis did not demonstrate an increased 
risk of malignancy [12]. 
Nevertheless, this case report illustrates the potential usefulness of infliximab in 
gaining rapid disease control and allowing time for rituximab to take effect, at least in 
some patients with necrotising scleritis. It also illustrates the increasing treatment 
options which are available to treat patients with refractory ocular inflammation, and 
supports the management of such patients in a multidisciplinary setting so that close 
contact with appropriate specialists can enable these treatments to be taken advantage 
of by patients in a safe and controlled environment. 
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Fig. 1. An active area of necrotising scleritis is visible in the superotemporal quadrant of the left eye, 
despite 1 mg/kg/day prednisolone and 2 recent doses of rituximab. 
 
 
 
Fig. 2. Six weeks after the institution of infliximab therapy, the necrotic area can be seen to have 
revascularised and healed. 
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